Ready to go, high expressing manufacturing biosimilar cell lines ready for development
Polpharma Biologics has developed a portfolio of high producing cell lines expressing biosimilar proteins, such as fusion proteins, enzymes and monoclonal antibodies which are available for out-licensing.
These biosimilar cell lines are generated on our proprietary CHO-based platform, CHO ® using (animal component free) of the shelf culture medium. The cell lines are GMP-ready, stable, high producing, fully documented and functionally characterized. All available QA approved documentation is accessible for our (potential) partners via a Virtual Data Room.
Ready for tech transfer
Biosimilar programs are ready for tech transfer to a CMO of your choice or you can use our own CDMO services to advance to the clinic rapidly. Our cell lines and programs in different development stages, can be found in the table below. If a biosimilar that you are interested in is not listed contact us as we may have it in late stage development or can develop a cell line for you.
Biosimilar to
Antibody
Herceptin®
Trastuzumab
Humira®
Adalimumab
Erbitux®
Cetuximab
Avastin®
Bevacizumab
Rituxan/MabThera®
Rituximab
Enbrel®
Etanercept
Synagis®
Palivizumab
Xolair®
Omalizumab
Yervoy®
Ipilimumab
Perjeta®
Pertuzumab
Opdivo®
Nivolumab
Keytruda®
Pembrolizumab
Outlicesing and partnerships available
Polpharma Biologics biosimilar cell lines are available for outlicensing and ready for manufacturing at a facility of your choice. Please get in touch to discuss any biosimilars of interest to you.
Warning against fraudulent internet recruitment activities:
Our attention has been drawn to the fraudulent activities of persons posing as recruitment agencies or Polpharma Biologics employees. The fraud involves sending people a request for personal information, making job offers and/or extorting fees for recruitment-related accommodation or preparation sessions ahead of an interview or assessment centre. We would like to make it clear that Polpharma Biologics never requires candidates to make payment during a recruitment process.
Read more here.
PL
EN
